Company: DARE
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001401914-25-000022
Chunk: 11

Company: Dare Bioscience, Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 11
---
Item 1. Condensed Consolidated Financial Statements (Unaudited)

Daré Bioscience, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

March 31,2025December 31,2024(unaudited)AssetsCurrent assetsCash and cash equivalents$10,329,967 $15,698,174 Other receivables105,234 229,982 Prepaid expenses1,387,348 2,519,707 Total current assets11,822,549 18,447,863 Property and equipment, net1,484,947 1,335,732 Operating lease right-of-use assets1,083,036 1,206,942 Finance lease right-of-use asset3,149,882 — Other non-current assets1,078,527 1,110,594 Total assets$18,618,941 $22,101,131 Liabilities and stockholders’ deficitCurrent liabilitiesAccounts payable$1,883,142 $1,455,832 Accrued expenses1,771,666 3,042,918 Deferred grant funding15,121,962 16,561,625 Current portion of liability related to the sale of future royalties91,907 — Current portion of lease liabilities, operating568,297 548,638 Current portion of lease liability, finance1,751,100 — Total current liabilities21,188,074 21,609,013 Deferred revenue, non-current1,000,000 1,000,000 Liability related to the sale of future royalties, net4,741,338 4,749,824 Lease liabilities long-term, operating603,295 754,383 Lease liability long-term, finance649,935 — Total liabilities28,182,642 28,113,220 Commitments and contingencies (Note 9)Stockholders' deficitPreferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding— — Common stock, $0.0001 par value; 240,000,000 shares authorized; 8,850,386 and 8,700,386 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively885 870 Additional paid-in capital170,519,070 169,705,480